Reid Hoffman, the LinkedIn co-founder and longtime Microsoft board member, is departing his position on the software giant's board to assume an active operational role at Manus, his artificial intelligence drug discovery startup. The move marks a significant commitment to the biotech sector and underscores a growing pattern of established tech investors transitioning from passive board positions into hands-on founder roles within AI-focused ventures. Hoffman's decade-long tenure on Microsoft's board proved highly profitable, but the decision to leave signals that emerging opportunities in AI drug discovery warrant his full-time attention and operational expertise rather than periodic board engagement.
Manus represents one of a proliferating wave of well-funded AI drug discovery platforms attracting significant venture capital. The startup joins competitors like Recursion Pharmaceuticals and Exscientia in targeting the multi-trillion-dollar pharmaceutical development market, where AI systems promise to accelerate target identification and compound design. While Manus's exact current valuation and latest round size remain undisclosed in available reporting, the sector has seen explosive funding momentum through 2024 and 2025, with mega-rounds exceeding $100 million becoming standard for enterprise AI and specialized vertical applications. Hoffman's personal involvement suggests confidence that AI drug discovery can achieve the kind of defensible, high-ACV business models increasingly driving venture returns, particularly as larger deal sizes require founder-level relationship management and strategic decision-making.
The shift to 'founder mode'—Hoffman's term for direct operational involvement—reflects a recognition that vertically specialized AI businesses demand more than capital and board-level strategic input. Full-time engagement with product development, customer acquisition through industry channels, and regulatory navigation appear essential for startups targeting high-stakes sectors like pharmaceuticals. Hoffman's exit from Microsoft's board, while losing him access to quarterly board compensation and equity appreciation, positions him to directly shape Manus's go-to-market strategy and scientific direction. The move illustrates how competitive AI drug discovery has become and how leading founders view the opportunity cost of passive investments versus active ownership stakes in transformative biotech ventures.